VOLUME 20 | NUMBER 8 | AUGUST 2014 nature medicine l e t t e r S The HIV-1 restriction factor SAM domain-and HD domaincontaining protein 1 (SAMHD1) 1,2 is proposed to inhibit HIV-1 replication by depleting the intracellular dNTP pool [3] [4] [5] . However, phosphorylation of SAMHD1 regulates its ability to restrict HIV-1 without decreasing cellular dNTP levels 6-8 , which is not consistent with a role for SAMHD1 dNTPase activity in HIV-1 restriction. Here, we show that SAMHD1 possesses RNase activity and that the RNase but not the dNTPase function is essential for HIV-1 restriction. By enzymatically characterizing Aicardi-Goutières syndrome (AGS)-associated SAMHD1 mutations and mutations in the allosteric dGTP-binding site of SAMHD1 for defects in RNase or dNTPase activity, we identify SAMHD1 point mutants that cause loss of one or both functions. The RNase-positive and dNTPase-negative SAMHD1 D137N mutant is able to restrict HIV-1 infection, whereas the RNase-negative and dNTPase-positive SAMHD1 Q548A mutant is defective for HIV-1 restriction. SAMHD1 associates with HIV-1 RNA and degrades it during the early phases of cell infection. SAMHD1 silencing in macrophages and CD4 + T cells from healthy donors increases HIV-1 RNA stability, rendering the cells permissive for HIV-1 infection. Furthermore, phosphorylation of SAMHD1 at T592 negatively regulates its RNase activity in cells and impedes HIV-1 restriction. Our results reveal that the RNase activity of SAMHD1 is responsible for preventing HIV-1 infection by directly degrading the HIV-1 RNA.
l e t t e r S
The HIV-1 restriction factor SAM domain-and HD domaincontaining protein 1 (SAMHD1) 1,2 is proposed to inhibit HIV-1 replication by depleting the intracellular dNTP pool [3] [4] [5] . However, phosphorylation of SAMHD1 regulates its ability to restrict HIV-1 without decreasing cellular dNTP levels [6] [7] [8] , which is not consistent with a role for SAMHD1 dNTPase activity in HIV-1 restriction. Here, we show that SAMHD1 possesses RNase activity and that the RNase but not the dNTPase function is essential for HIV-1 restriction. By enzymatically characterizing Aicardi-Goutières syndrome (AGS)-associated SAMHD1 mutations and mutations in the allosteric dGTP-binding site of SAMHD1 for defects in RNase or dNTPase activity, we identify SAMHD1 point mutants that cause loss of one or both functions. The RNase-positive and dNTPase-negative SAMHD1 D137N mutant is able to restrict HIV-1 infection, whereas the RNase-negative and dNTPase-positive SAMHD1 Q548A mutant is defective for HIV-1 restriction. SAMHD1 associates with HIV-1 RNA and degrades it during the early phases of cell infection. SAMHD1 silencing in macrophages and CD4 + T cells from healthy donors increases HIV-1 RNA stability, rendering the cells permissive for HIV-1 infection. Furthermore, phosphorylation of SAMHD1 at T592 negatively regulates its RNase activity in cells and impedes HIV-1 restriction. Our results reveal that the RNase activity of SAMHD1 is responsible for preventing HIV-1 infection by directly degrading the HIV-1 RNA.
Mutations in SAMHD1 cause AGS, which is a genetic autoimmune disorder that mimics a congenital viral infection 9, 10 . HIV-1 infection of myeloid and quiescent CD4 + T cells is restricted by SAMHD1 and can be counteracted by HIV-2 Vpx protein 1, 2 . SAMHD1 possesses a dGTP-dependent dNTPase activity 11, 12 , and studies have proposed that SAMHD1 blocks HIV-1 infection by depleting the intracellular dNTP pool [3] [4] [5] . Contrary to the proposed role for dNTPase activity in SAMHD1-mediated restriction of HIV-1, phosphorylation of SAMHD1 regulates the ability of this enzyme to restrict HIV-1 infection but does not alter cellular dNTP levels [6] [7] [8] . In addition, SAMHD1 is a nucleic acid-binding protein [13] [14] [15] and exhibits a nuclease activity in vitro against diverse nucleic acid substrates 16 . Although the physiological relevance of SAMHD1 nuclease activity remains unknown, the aforementioned characteristics suggest that SAMHD1 might bind to HIV-1 RNA and degrade this RNA or reverse transcription intermediates.
Most studies have not observed SAMHD1 nuclease activity [11] [12] [13] ; therefore, we tested whether SAMHD1 possesses nuclease activity. We incubated full-length, wild-type human SAMHD1 (SAMHD1 WT ) (Supplementary Fig. 1 ) with various types of synthetic nucleic acid substrates. SAMHD1 WT hydrolyzed both 20-and 30-mer singlestranded RNAs (ssRNAs) processively ( Fig. 1a and Supplementary  Fig. 2a) . We did not detect any nuclease activity on double-stranded RNA (dsRNA), single-stranded DNA (ssDNA), double-stranded DNA (dsDNA) and RNA-DNA hybrid substrates, whereas these substrates were digested by positive control nucleases ( Supplementary Fig. 2b -e) (substrate sequences are shown in Supplementary Table 1) . A previous study 16 showed that SAMHD1 degrades ssRNA, ssDNA and RNA in DNA-RNA hybrids; however, we observed that only ssRNAs, including in vitro-HIV-1 transcripts (Supplementary Fig. 3 ), were sensitive to SAMHD1 digestion when we repeated the experiments using the various types of 40-mer nucleic acid substrates described by Beloglazova et al. 16 ( Supplementary Fig. 4 ). These discrepancies might be due to differences in assay conditions or protein purification procedures; however, our results are consistent with the observation of Beloglazova et al. 16 that SAMHD1 cleaves ssRNAs in vitro. The degradation of ssRNA by SAMHD1 required Mg 2+ (Supplementary Fig. 5 ) and correlated with the presence of the SAMHD1 WT protein across chromatographic fractions (Supplementary Fig. 6 ). Considering the preferential binding of SAMHD1 to ssRNA compared with ssDNA as shown previously 13, 15 and the lack of interaction between endogenous SAMHD1 and dsRNA,
The ribonuclease activity of SAMHD1 is required for HIV-1 restriction dsDNA or RNA-DNA hybrids 15 , we concluded that SAMHD1 is an RNase that digests ssRNA.
Unlike dNTPase activity, RNase activity does not require the cofactor dGTP (Fig. 1a) ; therefore, we proposed that these two catalytic functions of SAMHD1 might be physically separable. We characterized AGS-associated SAMHD1 mutations and mutations near the allosteric sites for defects in RNase or dNTPase activity and identified several point mutations that caused loss of one or both functions. Mutations at residues 207 and 311 in the catalytic site abolished both RNase and dNTPase activities (Fig. 1b,c) . The allosteric mutant SAMHD1 D137N had no effect on the RNase activity but did abolish the dNTPase activity (Fig. 1b,c) , whereas the AGS-mutant SAMHD1 Q548A showed the opposite phenotype. Unlike the processive degradation seen in SAMHD1 WT and SAMHD1 D137N , the Q548A mutation caused the enzyme to digest ssRNA in a distributive manner featured by accumulation of intermediate-size fragments (16-19 nucleotides) (Fig. 1d) . Considering that a shift from a processive to distributive degradation often occurs under the conditions that decrease the affinity of an exonuclease for its substrates 17 , this switch in mode may be because of a lowered affinity of SAMHD1 Q548A for ssRNA. Indeed, recent studies have shown that SAMHD1 Q548A exhibits impaired ssRNA binding 15, 16 . Notably, dGTP inhibited the RNase activity of SAMHD1 on ssRNA substrates, and this inhibition correlated with a shift from a processive to a distributive hydrolysis (Fig. 1e) , In f and g, the data are presented as the mean ± s.d. of triplicate independent experiments. *P < 0.05 and **P < 0.001 compared with the mock-transfected control, using the two-tailed Student's t-test. npg l e t t e r S suggesting that dGTP interferes with the binding of ssRNA substrates to SAMHD1.
The identification of the SAMHD1 mutants that retain only one of two enzymatic activities enabled us to determine the discrete contribution of SAMHD1 RNase activity to HIV-1 restriction. For this analysis, we stably expressed SAMHD1 mutants in U937 pro-monocytic cells, which do not express endogenous SAMHD1 (refs. 1,3,6,7) (Supplementary Fig. 7) . Consistent with our in vitro data (Fig. 1c,d ), SAMHD1 D207N , SAMHD1 D311A and SAMHD1 D137N did not reduce the intracellular levels of dNTPs, whereas SAMHD1 Q548A did (Fig. 1f) . As expected, SAMHD1 D207N and SAMHD1 D311A did not restrict HIV-1 infection. Notably, SAMHD1 D137N restricted HIV-1 infection to nearly the same extent as SAMHD1 WT . SAMHD1 Q548A was unable to restrict HIV-1 infection despite its ability to decrease the cellular levels of dNTPs (Fig. 1g) . These data suggest that the RNase but not the dNTPase function of SAMHD1 is essential for HIV-1 restriction.
Quantification of viral cDNA intermediates by quantitative PCR (qPCR) showed that SAMHD1 D137N inhibited the synthesis of both early and late viral cDNA products (Supplementary Fig. 8 ), indicating that SAMHD1 RNase functions at the early steps of HIV-1 reverse transcription. Thus, we tested whether SAMHD1 RNase The purified RNAs in the anti-HA immunoprecipitates were quantified by qRT-PCR using HIV-1 gag-specific primers. In a, b, e and f, data are presented as the mean ± s.d. of triplicate independent experiments. *P < 0.05 and **P < 0.001 versus mock or shControl, two-tailed Student's t-test.
npg activity affects HIV-1 RNA levels. HIV-1 RNA levels were substantially reduced in cells expressing SAMHD1 WT or SAMHD1 D137N 3 and 6 h post-infection (h.p.i.) (Fig. 2a) , but SAMHD1 D207N , SAMHD1 D311A ,and SAMHD1 Q548A did not reduce the HIV-1 RNA level; these results were consistent with the result of FACS analysis (Fig. 1g) . To exclude primer-specificity bias, we used 12 pairs of primers spanning the entire HIV-1 genomic RNA (Supplementary Table 2 ) to amplify fragments from HIV-1-infected cells. The HIV-1 RNA level in SAMHD1 WT -expressing cells was distinctly lower compared with the mock-transfected cells (Supplementary Fig. 9 ). To exclude the effect of the viral reverse transcriptase RNase H activity on the HIV-1 RNA level, we used RNase H-defective HIV-1 (HIV-1 D443N ) in which D443 of reverse transcriptase was mutated to asparagine (D443N) 18 . The HIV-1 D443N RNA level was lower in SAMHD1 WTexpressing cells compared with mock-transfected cells (Fig. 2b) , indicating that SAMHD1 can degrade HIV-1 RNA in the absence of reverse transcription. RNA sequencing (RNA-seq) analysis also confirmed the degradation of HIV-1 RNA by SAMHD1. At 3 h.p.i., the relative read count of HIV-1 RNA in SAMHD1 WT -and SAMHD1 D137N -expressing cells was lower than that in mock-transfected or SAMHD1 D207N -expressing cells despite the considerable reduction of HIV-1 RNA levels in all cell types compared with the levels observed at 1 h.p.i. (Fig. 2c,d) . shRNA-mediated knockdown of SAMHD1 or Vpx-mediated degradation of endogenous SAMHD1 in THP-1 human monocytic cells also caused an approximately fourfold increase in the HIV-1 RNA level (Fig. 2e) . RNA immunoprecipitation (RIP) analysis 19 revealed a significant enrichment of HIV-1 RNA in the immunoprecipitates from cells expressing hemagglutinin (HA)-tagged SAMHD1 WT compared with HIV-1 RNA immunoprecipitated from mock-transfected cells (Fig. 2f) . The HIV-1 RNA enrichment was more pronounced for the SAMHD1 D207N -HA catalytic mutant, with an approximately eightfold increase (Fig. 2f) , suggesting that SAMHD1 associates with HIV-1 genomic RNA. In contrast, interaction of SAMHD1 Q548A -HA with HIV-1 RNA was significantly reduced when compared with that of SAMHD1 WT -HA (Fig. 2f) , suggesting that the impaired binding of SAMHD1 Q548A -HA to HIV-1 RNA accounts for its inability to cleave short ssRNA and HIV-1 RNA (Figs. 1d and 2a) .
Next, we analyzed the role of SAMHD1 RNase in degrading HIV-1 RNA in primary human monocyte-derived macrophages (MDMs) and CD4 + T cells. We analyzed the differentiation of MDMs and the activation state of CD4 + T cells by monitoring their surface markers ( Supplementary Figs. 10 and 11) . siRNA-mediated SAMHD1 silencing in MDMs markedly reduced their cellular SAMHD1 levels and rendered them more permissive to HIV-1 infection (Fig. 3a and  Supplementary Fig. 12 ), a result that is correlated with the increased stability of HIV-1 RNA (Fig. 3a) . The enhancement of HIV-1 RNA stability associated with SAMHD1 silencing ranged from approximately two to fourfold over levels seen in control siRNA-treated cells, depending on the donor (Fig. 3a) . Similarly to the results obtained using MDMs, SAMHD1 silencing in resting CD4 + T cells increased the infectivity of HIV-1 ( Fig. 3b and Supplementary Fig. 12) . In these cells, we observed increased HIV-1 RNA stability 3 h.p.i. (Fig. 3b) . The degradation of SAMHD1 by Vpx could also stabilize the viral RNAs of HIV-1 and HIV-1 D443N in resting CD4 + T cells (Fig. 3c) . These results show that the antiviral activity of SAMHD1 correlates with its RNase activity in primary MDMs and resting CD4 + T cells. Biochemical fractionation revealed that SAMHD1 localizes to both the cytoplasm and nucleus of MDMs and monocytes (Supplementary Fig. 13 ), which is consistent with previous observations 4, 13 . Considering that cytoplasmic SAMHD1 can block HIV-1 infection 20, 21 , these data suggest that after virus uncoating, SAMHD1 associates with and degrades HIV-1 RNA in the cytoplasm.
Phosphorylation of SAMHD1 at T592 causes loss of HIV-1 restriction without decreasing cellular dNTP levels [6] [7] [8] . We tested whether phosphorylation of SAMHD1 affects its RNase activity in HIV-1 restriction. In phorbol 12-myristate 13-acetate (PMA)-differentiated U937 cells, in which SAMHD1 WT is not phosphorylated on T592 (refs. 6,7), SAMHD1 WT blocked HIV-1 infection. In contrast, SAMHD1 T592D , which contains a phosphomimetic aspartic acid residue at T592, was unable to inhibit HIV-1 infection (Fig. 4a) , confirming previous results 6 . Notably, the stability of HIV-1 RNA was enhanced by three to fourfold in cells expressing SAMHD1 T592D compared with cells expressing SAMHD1 WT (Fig. 4b) . In contrast to this in vivo observation, the recombinant SAMHD1 T592D protein was as effective as SAMHD1 WT and the nonphosphorylatable SAMHD1 T592V in degrading ssRNA substrates in vitro (Fig. 4c) . RIP analysis revealed that SAMHD1 WT and SAMHD1 T592D bound to HIV-1 genomic RNA with similar affinities, indicating that phosphorylation of SAMHD1 T592 does not interfere with substrate binding (Fig. 4d) . npg l e t t e r S
The discrepancy between the in vivo and in vitro RNase activities suggests that phosphorylation of SAMHD1 might promote the recruitment of cellular factors that negatively regulate its RNase activity or interfere with the interaction of SAMHD1 with unidentified cofactors. Our results reveal that phosphorylation of SAMHD1 at T592 is a mechanism that negatively regulates its RNase activity in vivo and impedes HIV-1 restriction. The crystal structure of SAMHD1 reveals that this protein is dimeric and indicates a structural basis for allosteric activation of catalytic activity against dNTPs by dGTP binding 11 . In contrast, recent studies have demonstrated that SAMHD1 oligomerizes in a dGTP-dependent manner up to a tetramer and that the tetramerization of SAMHD1 is required for its dNTPase and anti-HIV-1 activities [22] [23] [24] . Notably, SAMHD1 with a mutation at the allosteric dGTP-binding site D137 did not undergo oligomerization and was mostly monomeric in the presence of dGTP 22 . Mutation of D137 (SAMHD1 D137N ) abolishes SAMHD1 dNTPase but not RNase activity (Fig. 1) , indicating that unlike for the dNTPase activity, the tetramerization of SAMHD1 is not necessary for its RNase activity. On the basis of previous data and our results, we propose that SAMHD1 is a dual-function enzyme whose mutually exclusive and predominant activities depend on the dGTP pool. At low dGTP levels, SAMHD1 exists as monomers or dimers that harbor active RNase but not dNTPase activity, enabling HIV-1 restriction through the cleavage of HIV-1 RNA. At high dGTP levels, SAMHD1 tetramerizes, yielding an enzyme with an inactive RNase (Fig. 1e) but active dNTPase function (Fig. 4e ). An alternative but not mutually exclusive possibility is that the ssRNA and dNTP substrates might compete with each other for a common active site on the enzyme. dGTP is both a substrate and an activator of the SAMHD1 dNTPase function 11, 12 ; this model is consistent with observations that high levels of dGTP impair the binding of SAMHD1 to nucleic acid substrates in vitro 6, 16 , that the switch from a processive to distributive degradation of ssRNA in a dGTP-dependent manner (Fig. 1e) is indicative of competitive inhibition of ssRNA binding by dGTP, and that mutations in the catalytic site abolish both RNase and dNTPase activities (Fig. 1) . In this respect, the partial alleviation of SAMHD1-mediated HIV-1 restriction by the addition of exogenous deoxynucleosides 3 might be an indirect consequence of impaired RNA substrate binding caused by increased dGTP levels. These two hypotheses may also explain why SAMHD1 blocks HIV-1 infection in noncycling cells with low dNTP levels, such as dendritic cells and macrophages 1 , but not in cycling cells with high dNTP levels 4, 6, 25 . Another explanation might be that in noncycling cells, dNTP limitation would slow down reverse transcription, and this could allow a sufficient time window for the action of SAMHD1 RNase against HIV-1 RNA. The identification of SAMHD1 as an RNase suggests that SAMHD1 is involved in nucleic acid metabolism related to the prevention of an innate immune response; therefore, our results provide insight into the mechanisms underlying HIV-1 restriction and the pathogenesis of AGS.
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